表紙
市場調查報告書
商品編碼
907772

脊髓筋委縮小症 (SMA) :流行病學預測 ∼2028年

Spinal Muscular Atrophy: Epidemiology Forecast to 2028

出版日期: | 出版商: GlobalData | 英文 21 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的脊髓筋委縮小症 (SMA)的診斷案例數,預計將從2018年的25,783件增加到2028年26,690件,並以0.35%的年複合成長率 (CAGR) 增加。

本報告提供全球主要7個國家的脊髓筋委縮小症 (SMA) 市場相關調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 世界、過去趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
    • 預測的前提條件與手法:確診的患者數
  • SMA的流行病學預測
    • 確診的患者數
    • 確診的患者數:性別
    • 確診的患者數:各類型
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER206-19

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA is 5q SMA, linked to chromosome 5q and its phenotype is classified into four grades of severity (type I, type II, type III, and type IV) based on age of onset and motor function achieved. Additionally, SMA type 0 is an uncommon form of very severe SMA with prenatal onset. In rare cases SMA is also caused by the mutation in another gene and known as non-5q SMA.

The diagnosed prevalent cases of type II spinal muscular atrophy (SMA) made up the highest proportion with 10,574 cases, nearly one half of all diagnosed prevalent cases of SMA in the seven major markets (US, France, Germany, Italy, Spain, the UK and Japan) in 2018. More than one third of type II SMA cases, which was around 4,136 cases, were contributed by the US followed by Japan. Type IV SMA had the least amount of cases among the subtypes which was only one tenth of all diagnosed prevalent cases of SMA.

Diagnosed prevalent cases of SMA are set to increase in the 7MM from 25,783 cases in 2018 to 26,690 in 2028, at an Annual Growth Rate (AGR) of 0.35%. The increased burden of type II SMA cases is partly attributable to the high mortality of type I SMA combined with the increased frequency of the specific type II SMA phenotype due to gene mutations.

The introduction of new therapies for treating SMA is likely to impact the prevalence of SMA. As more people become aware of the disease, diagnosis and patient enrolment in registries may improve. This could have significant resource implications for health care planning.

Latest report "Spinal Muscular Atrophy: Epidemiology Forecast to 2028", provides an overview of the risk factors and global trends of Spinal Muscular Atrophy (SMA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).

The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SMA segmented by sex (for all ages) in these markets. The diagnosed prevalent cases of SMA are further segmented by type (type I, type II, type III and type IV).

Scope:

  • The Spinal Muscular Atrophy Epidemiology Report provides an overview of the risk factors and global trends of Spinal Muscular Atrophy (SMA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SMA segmented by sex (for all ages) in these markets. The diagnosed prevalent cases of SMA are further segmented by type (type I, type II, type III and type IV).
  • The SMA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy:

The SMA Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global SMA market.
  • Quantify patient populations in the global SMA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SMA therapeutics in each of the markets covered.
  • Understand magnitude of SMA population by its type.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Spinal Muscular Atrophy: Executive Summary

  • 2.1. Related Reports
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global and Historical Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of SMA
  • 3.5. Epidemiological Forecast for SMA (2018-2028)
    • 3.5.1. Diagnosed Prevalent Cases of SMA
    • 3.5.2. Sex-Specific Diagnosed Prevalent Cases of SMA
    • 3.5.3. Diagnosed Prevalent Cases of SMA by Type
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of Analysis
    • 3.6.3. Strengths of Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head and EVP of Healthcare Operations and Strategy
  • 4.3. About GlobalData
  • 4.4. Contact Us
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for SMA

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of SMA, N, Both Sexes, All Ages, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Prevalence of SMA, %, Both Sexes, All Ages, 2018
  • Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Preval